|
BODY SYSTEM / ADVERSE
EXPERIENCE |
Bupropion
sustained-release Dosing Group |
||
|
100-200 mg/d (N=350) |
300-400 mg/d (N=343) |
Placebo (N=235) |
|
|
Infections |
|||
|
Upper
Respiratory Infection |
7.7% |
7.9% |
7.2% |
|
Flu
Syndrome |
4.3% |
2.6% |
2.6% |
|
Special
Senses |
|||
|
Tinnitus |
3.4% |
5.2% |
1.7% |
|
Taste
Perversion |
1.1% |
2.0% |
0% |
|
Blurred
Vision |
2.6% |
2.0% |
2.6% |
|
Musculoskeletal |
|||
|
Arthralgia |
2.3% |
2.0% |
0.9% |
|
Myalgia |
3.4% |
4.4% |
3.4% |
|
Urinary
System Disorders |
|||
|
Urinary
Tract Infection |
1.4% |
0.9% |
0.4% |
|
Urinary
Frequency |
1.7% |
3.5% |
1.7% |
|
Reproductive Disorders, Male (percentage based on # male patients (BUP SR
100-200=122, BUP SR 300-400=115) |
|||
|
Impotence |
1.6% |
0.9% |
0% |
|
Reproductive Disorders, Female (percentage based on # female patients (BUP SR
100-200=228, BUP SR 300-400=228) |
|||
|
Impotence |
1.8% |
2.6% |
4.7% |
Common,
Drug-Related Adverse Events
The
following adverse events occurred at a rate greater than five per cent in at least
on bupropion release-sustained dose group, and were seen at least
twice as frequently in one ore more bupropion sustained-release dose groups as
among placebo patients:
Agitation
Dry Mouth
Pharyngitis
Rash
Sinusitis
Sweating
Tinnitus
Tremor
Back a Page
Next Page
Back to Wellbutrin SRŪ NDA Index Page
Back to Main
Index